Improvement of left ventricular global longitudinal strain (LV GLS) after 6-months of GLP-1 RAs treatment in diabetes mellitus type 2

Abstract Funding Acknowledgements Type of funding sources: None. Background Glucagone Like Peptide-1 Receptor Agonists (GLP-1RAs) are incretine-based glucose-lowering drugs widely used in the treatment Diabetes Mellitus type 2 (DM2). Several cardiovascular outcomes trials demonstrated that GLP-1RAs capable to induce a reduction major adverse events (MACE) DM2 patients with atherosclerotic diseases (ASCVD) or high/very high (CV) risk. However, direct effect GLP1-RAs on cardiac function needs be further explored. Purpose The aim this study was investigation effects semaglutide dulaglutide systolic and ASCVD CV Methods We conducted proof-of-concept, observational, perspective, monocentric by enrollment 22 treated from December 2019 March 2020 coming outpatient diabetology clinic our hospital. Each patient underwent transthoracic echocardiographic evaluation before drug initiation, then reassessed after mean follow-up 6 months two cardiologists experience echocardiography. examination focused detection left ventricular ejection fraction (LVEF) global longitudinal strain (LV GLS) speckle tracking echocardiography (STE) (figure 1). Results Mean age sample 65 ± 10 years, small prevalence male sex (64% cases). A huge number had arterial hypertension (100%), dyslipidaemia (95%), family history disease (91%), obesity (86%), smoking habit (68%) previous myocardial infarction (MI). Chronic Obstructive Pulmonary Disease (COPD) most frequent comorbidity (32% mild LV concentric hypertrophy highly represented [median interventricular septum 12 (IQR 1) mm]. No one valvular diseases, except for minimum/mild tricuspid mitral regurgitation. relevant alterations were seen right sections. LVEF normal majority patients, median value 59% 7%). GLS slightly under range (−18,0% 1,8%). After 6-months dulaglutide, documented clinical statistically significant improvement (mean difference −1,4% 1,1%; p<0,001), tending towards (19,5% 2,1%) 2). changes other parameters evaluated. Conclusions In setting subclinical dysfunction defined is common may evolve diabetic cardiomyopathy. Semaglutide should considered as antidiabetic order improve function. Further studies larger size longer ongoing confirm these preliminary results.